RXI Licenses RNAi Delivery Mode

Luke Timmerman7/27/09

RXi Pharmaceuticals, the Worcester, MA-based developer of RNA interference drugs, said today it has obtained an exclusive worldwide license to RNAi delivery technologies from Advirna. The technology is supposed to make it easier to deliver RNAi without liposomes, nanoparticles, or other methods that add complexity, RXi said (NASDAQ: RXII). Terms of the deal weren’t disclosed.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.